Publications in collaboration with researchers from Oregon Health & Science University (8)

2025

  1. Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

    The New England journal of medicine, Vol. 392, Núm. 18, pp. 1777-1788

2021

  1. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

    Leukemia, Vol. 35, Núm. 1, pp. 18-30

2020

  1. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma

    American Journal of Hematology, Vol. 95, Núm. 5, pp. 503-509

  2. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 20, Núm. 8, pp. 509-518

  3. Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

    Leukemia and Lymphoma, Vol. 61, Núm. 8, pp. 1885-1893

2018

  1. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR

    Haematologica, Vol. 103, Núm. 12, pp. 2079-2087

2016

  1. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial

    The Lancet, Vol. 387, Núm. 10027, pp. 1551-1560

2015

  1. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

    Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051